Pfizer Inc. (NYSE:PFE) Shares Sold by Congress Park Capital LLC

by · The Cerbat Gem

Congress Park Capital LLC decreased its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 20.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,265 shares of the biopharmaceutical company’s stock after selling 2,375 shares during the quarter. Congress Park Capital LLC’s holdings in Pfizer were worth $268,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of PFE. Brevan Howard Capital Management LP lifted its stake in shares of Pfizer by 61.6% in the fourth quarter. Brevan Howard Capital Management LP now owns 43,091 shares of the biopharmaceutical company’s stock worth $1,241,000 after acquiring an additional 16,422 shares in the last quarter. Bell Investment Advisors Inc raised its stake in Pfizer by 9.1% during the fourth quarter. Bell Investment Advisors Inc now owns 5,958 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 497 shares in the last quarter. Bayesian Capital Management LP raised its stake in Pfizer by 57.0% during the fourth quarter. Bayesian Capital Management LP now owns 175,200 shares of the biopharmaceutical company’s stock valued at $5,044,000 after buying an additional 63,600 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in Pfizer by 26.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 466,252 shares of the biopharmaceutical company’s stock valued at $13,423,000 after buying an additional 96,185 shares in the last quarter. Finally, Guardian Wealth Management Inc. raised its stake in Pfizer by 245.7% during the fourth quarter. Guardian Wealth Management Inc. now owns 2,247 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,597 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock traded down $0.27 during trading hours on Friday, hitting $29.07. 12,099,729 shares of the stock traded hands, compared to its average volume of 37,304,969. Pfizer Inc. has a one year low of $25.20 and a one year high of $33.92. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market cap of $164.73 billion, a P/E ratio of -484.00, a P/E/G ratio of 1.30 and a beta of 0.67. The stock has a 50-day simple moving average of $29.06 and a 200 day simple moving average of $28.37.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Equities analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.78%. Pfizer’s payout ratio is presently -2,800.00%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Thursday, October 3rd. Finally, UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.54.

Get Our Latest Analysis on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).